Riskpilot← Back to searchSign inGet full accessHelleday Laboratories AB
ABActiveOrg 5569742629Norrbackagatan 70 CResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20140 employees
Revenue 2024
SEK 0
EBITDA margin
—
-100% vs 2023
Equity ratio
98.9%
Financial strength
Net profit 2024
SEK -1K
0% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -2K | -100% |
| Net profit | SEK -1K | +0% |
| Total assets | SEK 89K | -1% |
| Equity | SEK 88K | -1% |
| Employees | 0 | — |
Legal name
Helleday Laboratories AB
Org number
5569742629
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 juni 2014
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva forskning, utveckling och försäljning av produkter inom det medicinska området.
Address
Norrbackagatan 70 C
Email
admin@oxcia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | −1 | −1 | −1 | −2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −1 | −1 | −1 | −2 |
| Net financials | — | — | — | — | 1 |
| Profit before tax | 0 | −1 | −1 | −1 | −1 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −1 | −1 | −1 | −1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 94 | 92 | 91 | 90 | 89 |
| Equity | 93 | 92 | 90 | 89 | 88 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 | 1 | 1 | 1 | 1 |
| Total debt | 1 | 1 | 1 | 1 | 1 |
EBITDA margin
-200000.0%
This company
15.8%
Market median
-1265923% vs market
20202024
Equity ratio
98.9%
This company
38.2%
Market median
+159% vs market
20202024
Return on equity
-1.1%
This company
18.4%
Market median
-106% vs market
20202024
Net profit margin
-100000.0%
This company
8.1%
Market median
-1234668% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
KM Chief Auditor | Chief Auditor | 2020 – 2020 |
NA Chief Auditor | Chief Auditor | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2025 | |
| Board of Directors | 2020 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Helleday Laboratories AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Magnus Karlström | Chief Auditor | 0 companies |
| Nils Andreas Nyberg Selvring | Chief Auditor | 0 companies |
| Olof Håkan Nordlander | Deputy Board Member | 0 companies |
| Ulrika Kristina Berglund | Board of Directors | 0 companies |
| Emil Gustav André Lindmark | Deputy Board Member | 0 companies |
| Jan Gustaf Zetterberg | Board of Directors | 0 companies |